Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir

Antimicrob Agents Chemother. 2011 Mar;55(3):1293-5. doi: 10.1128/AAC.00942-10. Epub 2010 Dec 28.

Abstract

We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Drug Resistance, Viral / genetics
  • Genotype
  • HIV Infections / drug therapy
  • HIV Infections / genetics
  • HIV Integrase / genetics*
  • HIV-2 / drug effects*
  • HIV-2 / pathogenicity
  • Humans
  • Molecular Sequence Data
  • Pyrrolidinones / therapeutic use*
  • Raltegravir Potassium

Substances

  • Antiviral Agents
  • Pyrrolidinones
  • Raltegravir Potassium
  • HIV Integrase

Associated data

  • GENBANK/HQ694834